FDA To Face Congressional Scrutiny Over Cordarone “MedGuide”
This article was originally published in The Pink Sheet Daily
Executive Summary
The Senate Finance Committee is interested in FDA’s handling of risk information for Wyeth’s anti-arrhythmic. FDA and Wyeth say development of a patient “MedGuide” is near completion.